Tandem Diabetes Care TNDM Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$20.39M+84.4% | -$589K— | -$21.17M+9.0% | -$52.4M-70.1% | -$130.56M-206% | ||
| $4.5M+4.5% | $4.5M+5.9% | $4.49M+6.7% | $4.37M+6.3% | $4.31M+6.6% | ||
| $15.66M-38.6% | $20.11M-28.6% | $21.14M-19.6% | $25.64M+3.0% | $25.49M+15.7% | ||
| $576K+14.1% | $446K-11.2% | $444K-11.6% | $465K+6.9% | $505K-22.3% | ||
| $2.11M+47.4% | $2.73M+2.1% | $3.17M-11.5% | $2.15M+40.7% | $1.43M-34.9% | ||
| -$22.68M-309% | $42.01M+248% | $1.28M-88.9% | $2.67M-61.3% | $10.84M+211% | ||
| -$1.93M+79.9% | -$7.56M-1,171% | -$5.19M+49.9% | -$2.46M-130% | -$9.6M-204% | ||
| $13.75M+107% | $5.82M+504% | -$9.33M-682% | —— | $6.64M+297% | ||
| -$14.74M-7.6% | -$861K— | $12.85M-18.5% | —— | -$13.71M-729% | ||
| $8.52M+1,287% | $10.47M+2,412% | -$61K+82.4% | -$2.81M-753% | -$718K-404% | ||
| $762K+18.3% | —— | $226K— | $4.21M+5,294% | $644K-22.7% | ||
| $1.8M-11.9% | $3.32M+226% | $617K-51.6% | —— | $2.05M+3,837% | ||
| -$1.08M+32.5% | -$686K+97.8% | -$1.39M+40.2% | -$1.11M-25.3% | -$1.6M-329% | ||
| -$3.87M-9.1% | -$4.55M-122% | -$2.72M— | -$3.38M— | -$3.54M— | ||
| $7.89M+57.9% | $10.21M-4.6% | $614K-79.1% | $3.41M+10.4% | $5M+466% | ||
| $11.05M+160% | —— | —— | -$9.5M-80.0% | -$18.28M-129% | ||
| $6.27M+111% | $6.69M+118% | $4.09M-21.9% | $6.21M-4.0% | $2.97M-33.5% | ||
| $216.13M+2,187% | $29.66M+129% | $29.51M-59.9% | $17.05M-81.8% | $9.45M-88.8% | ||
| $26.95M-58.6% | $56.49M-16.2% | $54.14M-8.2% | $81.38M-15.6% | $65.07M-22.2% | ||
| $0-100% | $0— | $0— | $0— | $75.22M— | ||
| -$195.45M-2,228% | —— | $20.54M+203% | $58.13M+1,742% | $9.19M+282% | ||
| $291.16M— | $0— | $0— | $0— | $0-100% | ||
| $274.16M+5,948% | $0-100% | -$1.57M— | -$39.71M— | -$4.69M-135% | ||
| -$1.08M+42.8% | $1.27M-41.4% | $605K+159% | $1.62M+202% | -$1.88M-344% | ||
| $88.69M+666% | —— | $27.84M+1,974% | —— | -$15.66M-14,208% | ||
| —— | $117K-93.5% | $47K-59.1% | $3.33M+265% | $1.56M+480% | ||
| $576K+14.1% | $446K-11.2% | $444K-11.6% | $465K+6.9% | $505K-22.3% | ||
| -$3.87M-9.1% | -$4.55M-122% | -$2.72M— | -$3.38M— | -$3.54M— | ||
| -$14.74M-7.6% | $5.8M+4.3% | $12.85M-18.5% | $1.06M-11.2% | -$13.71M-729% | ||
| $7.89M+57.9% | $10.21M-4.6% | $614K-79.1% | $3.41M+10.4% | $5M+466% | ||
| $762K+18.3% | —— | $226K— | $4.21M+5,294% | $644K-22.7% | ||
| $19M+739% | —— | $9.79M— | $84K-87.6% | $2.26M-44.8% | ||
| $747K-34.9% | $1.75M+1.1% | $303K-67.9% | $632K+181% | $1.15M+165% | ||
| $0-100% | —— | —— | —— | $6.7M— | ||
| $2.11M+47.4% | $2.73M+2.1% | $3.17M-11.5% | $2.15M+40.7% | $1.43M-34.9% | ||
| $0-100% | $0— | $0— | $0— | $75.22M— | ||
| $0-100% | $35.12M— | —— | —— | $43.46M— | ||
| $216.13M+2,187% | $29.66M+129% | $29.51M-59.9% | $17.05M-81.8% | $9.45M-88.8% | ||
| $26.95M-58.6% | $56.49M-16.2% | $54.14M-8.2% | $81.38M-15.6% | $65.07M-22.2% | ||
| $1.7M-63.8% | —— | —— | —— | $4.69M+179% | ||
| $15.3M— | $0— | $0— | $0— | $0-100% | ||
| $842K-79.9% | $2.87M— | —— | —— | $4.2M+30.5% | ||
| -$1.08M+32.5% | -$686K+97.8% | -$1.39M+40.2% | -$1.11M-25.3% | -$1.6M-329% | ||
| $7.89M+57.9% | $10.21M-4.6% | $614K-79.1% | $3.41M+10.4% | $5M+466% | ||
| $13.3M— | —— | —— | $13.3M— | $0— | ||
| $1.85M+1.8% | $0— | $26.17M+2,887% | -$1.82M-222% | $1.82M-20.7% | ||
| $290K— | —— | —— | —— | —— | ||
| $4.79M+123% | —— | —— | -$15.7M-33.7% | -$21.24M-70.6% | ||
| $4.79M+123% | —— | —— | -$15.7M-33.7% | -$21.24M-70.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Tandem Diabetes Care generate?
- Tandem Diabetes Care (TNDM) generated -$6.0M in operating cash flow over the trailing twelve months.
- What is Tandem Diabetes Care's free cash flow?
- After $23.3M of capital expenditures, Tandem Diabetes Care's free cash flow was -$24.5M over the trailing twelve months, down 62.7% year over year.
- Where does Tandem Diabetes Care's cash flow data come from?
- Every line is extracted from Tandem Diabetes Care's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
